Aflibercept for the Treatment of Age-Related Macular Degeneration

Abstract

Aflibercept is a novel, recombinant, fusion protein that consists of portions of vascular endothelial growth factor (VEGF) receptor (R) 1 and VEGFR2 extracellular domains fused to the Fc portion of human immunoglobulin G1. It exhibits higher affinity for VEGF-A/-B and binds all the VEGF isoforms (VEGF-B and -C, placental growth factor). The efficacy of aflibercept was assessed in two randomized, double-masked, multicenter, active-controlled, clinical trials in patients with choroidal neovascularization due to exudative age-related macular degeneration (AMD) and compared it’s efficacy to ranibizumab, which is already Food and Drug Administration (FDA)-approved for patients with wet AMD. In the two trials known as VIEW 1 and VIEW 2, aflibercept was as effective when dosed as 2 mg every 8 weeks after 3 monthly loading doses compared to monthly ranibizumab. Aflibercept was well tolerated with very rare systemic adverse events, including arterial thromboembolic events (ATEs). The incidence of ATEs was 1.8% during the first year of the clinical trials and included non-fatal strokes, non-fatal myocardial infarction, or death from vascular events or an unknown cause. In November 2011, aflibercept received FDA approval and is currently used in clinical practice for patients with wet AMD.

Introduction

Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in the developed world [1]. As the population ages, AMD has become the most common cause of vision loss [2]. In the United States (US), it affects more than 1.75 million people [3] and is estimated to affect approximately 14 million people worldwide. There are two forms of AMD: the non-neovascular or dry form, which is the most common, and the neovascular or wet form. The wet form of AMD is responsible for the majority of severe vision loss. Choroidal neovascularization (CNV) is the hallmark of neovascular AMD. CNV is characterized by growth of abnormal blood vessels under the macula with disruption of the blood retinal barrier, bleeding, exudation, and eventually scarring.

CNV has been classified into two forms: classic and occult CNV. The classification scheme was used in early AMD clinical trials. In classic CNV, the lesions show a well-demarcated appearance with early hyperfluorescence that progressively leaks dye to obscure it’s boundaries in late views of the fluorescein angiogram. Occult CNV appears as either late leakage from an undetermined source at the level of the retinal pigment epithelium (RPE) or as ill-defined early leakage with less profuse leakage in late views as in classic CNV. Patients can have 100% classic or occult CNV, but many will have mixed forms of CNV [4].

The pathogenesis of CNV in the setting of AMD is poorly understood. However, there are currently many reports suggesting that vascular endothelial growth factor (VEGF) plays an essential role [5–14]. Animal studies have demonstrated that VEGF over expression in the RPE leads to CNV [15, 16]. In mouse and monkey models of laser-induced CNV, intravitreal injections of an anti-VEGF-A antibody prevented the development of CNV and reduced leakage from pre-existing CNV [17–20]. Since the establishment of VEGF as an important factor in the development of neo-vascularization, several drugs have been developed to target this molecule [21] and prevent the devastating consequences of ocular neovascularization.

Ranibizumab and bevacizumab are both VEGF inhibitors used for the treatment of AMD. Ranibizumab is a recombinant, humanized, affinity-matured, antibody fragment (Fab) that neutralizes all active isoforms of VEGF-A, and bevacizumab is a full-length, recombinant, humanized, monoclonal antibody that binds to and blocks the action of all isoforms of VEGF-A [22]. Bevacizumab is used off-label for AMD as it has only received Food and Drug Administration (FDA) approval for the treatment of cancer. Two pivotal phase 3 clinical trials, MARINA [23] and ANCHOR [24], led to the FDA approval of ranibizumab. The MARINA study looked at minimally classic and occult CNV lesions comparing monthly ranibizumab to sham injections while the ANCHOR study evaluated monthly ranibizumab injections versus sham injections combined with verteporfin photodynamic therapy (PDT) in predominantly classic CNV due to AMD. The results were impressive and in both trials 94% of treated patients lost less than 15 letters of best-corrected visual acuity (BCVA) on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at 12 and 24 months. Although bevacizumab is used off-label [25, 26], the clinical equivalence of monthly bevacizumab and ranibizumab was recently demonstrated in the National Eye Institute’s Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) [27]. CATT was a 2-year, multicenter, randomized clinical trial that showed monthly dosing of both medications to be equivalent in terms of BCVA. Patients treated with ranibizumab gained +8.5 letters on the ETDRS chart whereas patients treated with bevacizumab gained +8.0 letters after 1 year of monthly injections.

Methods

The authors reviewed medical literature using PubMed and pertinent Internet postings combined with analysis of key studies regarding the use of aflibercept for the treatment of exudative AMD. The main keywords used were aflibercept, neovascular age-related macular degeneration, ranibizumab, vascular endothelial growth factor, wet age-related macular degeneration.

Fusion Proteins

Anti-VEGF monoclonal antibodies act via direct interaction with binding domains on either soluble VEGF ligands or membrane-bound receptors. In contrast, fusion proteins act as decoy receptors, binding with high affinity to the VEGF-A ligand; thus, preventing binding and subsequent activation of VEGF receptor (VEGFR) 1 and VEGFR2. The only VEGF fusion protein currently in clinical use is aflibercept [28].

Introduction to Aflibercept

Initially, four VEGF trap molecules were constructed [29]. The parental VEGF Trap was synthesized as a fusion protein combining the constant region (Fc) of immunoglobulin G (IgG)1 with the first three domains of VEGFR1. It was found to have very strong, picomolar-binding affinity for the VEGF ligand. However, it had a significant positive charge and as a consequence bound nonspecifically to negatively charged extracellular matrix proteins, resulting in short systemic half-life (t½). From the rest of the fusion proteins, the modification that included the Fc region of IgG1 fused with domain two of VEGFR1 and domain three of VEGFR2 was shown to have high affinity for the VEGF-A ligand and less positive charge. This modification increased the t½ of the protein and its in vivo activity. This fusion protein is currently manufactured as aflibercept, which exhibits higher affinity for VEGF-A/-B and binds all the VEGF isoforms [VEGF-B and -C, placental growth factor (PlGF)] (Fig. 1).

Fig. 1.

Aflibercept mechanism of action. Aflibercept binds to VEGF A-D and PIGF and prevents binding to the receptors and further activation of the angiogenesis cascade. ERK extracellular signal-regulated kinase, IgG1 immunoglobulin G1, PI3K phosphatidylinositol 3-kinase, PIGF placental growth factor, MEK Mitogen-activated protein/extracellular signal-regulated kinase kinase, mTOR mammalian target of rapamycin, VEGF vascular endothelial growth factor, VEGFR vascular endothelial growth factor receptor

Chemistry and Pharmacokinetics

Aflibercept is a soluble fusion protein. It has a molecular weight of 115 kDa and is manufactured from Chinese hamster ovary cells that overexpress the fusion protein. Aflibercept ophthalmic molecule is identical in structure to the cancer drug, ziv-aflibercept; however, it undergoes a different purification process and the formulation contains different buffer solutions that are less irritating when injected intravitreally.

The pharmacokinetic properties of aflibercept were initially determined by injecting VEGF TrapR1R2 (aflibercept 4 mg/kg) subcutaneously into mice. The maximum plasma concentration (C _max) and area under the concentration–time curve (AUC) were 16 μg/mL and 36.28 μg days/m, respectively. Kd for the predominant VEGF isoform in humans, VEGF165, was 0.5 pM [30]. Bioavailability following intravenous and subcutaneous dosing was nearly identical [31]. Following intravitreal administration of aflibercept (2 mg per eye), mean plasma C _max for free aflibercept was 0.02 μg/mL and was attained in 1–3 days. The t½ of aflibercept following intravitreal administration in humans is unknown and the predicted t½ is based on mathematical models [32, 33]. In rabbits, the intravitreal t½ of aflibercept is 4.6 versus 3 days for ranibizumab (Table 1) [34].

Table 1.

Pharmacokinetic and pharmacodynamic characteristics of aflibercept [34]

• Formulation: intravitreal injection

• Dose: 2 mg in 0.05 mL

• Dosing: every month for 3 months and then every 2 months

Pharmacokinetics

• Time to peak intraocular concentration: immediately following dose

• Volume of distribution: 4 mL

• Half-life: 4.6 days

Pharmacodynamics

• Targets: VEGFA-D, PIGF

• Effect: prevents VEGF receptor activation and stimulation of the angiogenesis cascade

PIGF placental growth factor, VEGF vascular endothelial growth factor

Aflibercept did not accumulate in the plasma when administered as repeated intravitreal doses every 4 weeks. Pharmacokinetic studies showed that the VEGF Trap molecule forms a 1:1 stable and inert complex with the VEGF-A ligand [35].

Clinical Efficacy and Safety

Phase 1/2 Studies

In a phase 1, randomized, double-blind, placebo-controlled trial in 25 patients with subfoveal CNV from AMD, intravenous aflibercept (1.0 or 3.0 mg/kg) achieved a dose-dependent decrease in retinal thickness on optimal coherence tomography (OCT). However, the study was discontinued due to dose-dependent systemic toxicity, with one patient developing hypertension and another proteinuria [36]. The safety, tolerability, and biological activity of intravitreal VEGF Trap-Eye in the treatment of neovascular AMD were evaluated in the Clinical Evaluation of Anti-angiogenesis in the Retina-1 (CLEAR-IT-1) study [37]. During this phase 1 study, 21 patients were monitored for safety, changes in foveal thickness on OCT, BCVA, and lesion size on fluorescein angiography (FA) for 6 weeks. No adverse systemic or ocular events were noted and visual acuity remained stable or improved ≥3 lines in 95% of patients with a mean increase in BCVA of 4.6 letters at 6 weeks [36]. Patients had a substantial decrease in foveal thickness on OCT.

This was followed by the phase 2 CLEAR-IT 2 trial, a prospective, randomized, multicenter, trial evaluating VEGF Trap-Eye at different doses and dosing intervals. Patients (n = 157) were randomized to five dose groups and treated with VEGF Trap-Eye in one eye. Two groups received monthly doses of either 0.5 or 2.0 mg for 12 weeks (at weeks 0, 4, 8, and 12) and three groups received 3-monthly doses of 0.5, 2.0, or 4.0 mg for 12 weeks (at weeks 0 and 12). Following this initial dosing period, patients were treated with the same dose of VEGF Trap-Eye on an as-required basis until week 52. After 12 weeks of treatment, there was a mean decrease in central retinal thickness of 119 μm from baseline in all groups. Improvements in visual acuity and retinal thickness were greater in the monthly dosing groups compared with the 3-monthly dosing groups, showing a clear benefit from initial monthly injections. Patients initially dosed on a 2.0 mg monthly schedule received an average of 1.6 more injections and those initially dosed on a 0.5 mg monthly schedule received an average of 2.5 injections. The median time to first reinjection in all groups was 129 days and 19% of patients required no more injections at week 52. Patients in the 2 monthly dosing groups also exhibited mean decreases in retinal thickness of 143 μm in the 2.0 mg group (P < 0.0001) and 125 μm in the 0.5 mg group (P < 0.0001) at 52 weeks as measured by OCT [38, 39].

Phase 3

VIEW 1 and VIEW 2 (VEGF Trap-Eye: Investigation of efficacy and safety in wet AMD) were pivotal phase 3, double-masked, randomized, multicenter studies comparing aflibercept and ranibizumab in patients with wet AMD. VIEW 1 enrolled 1,217 patients in the US and Canada and VIEW 2 enrolled 1,240 patients in the European Union, Asia Pacific, Japan, and Latin America. Both studies evaluated the percentage of patients who maintained visual acuity, defined as loss of fewer than 15 letters of BCVA on the ETDRS chart (3 lines) at 52 weeks. Patients were treated with three different aflibercept dosing regimens, 0.5 mg every 4 weeks, 2 mg every 4 weeks, and 2 mg every 8 weeks (following 3 initial monthly injections), compared to ranibizumab 0.5 mg every 4 weeks. At 52 weeks, the VIEW 1 study showed that in the aflibercept groups, vision was maintained in 96% of patients receiving 0.5 mg monthly, 95% of patients receiving 2 mg monthly, and 95% of patients receiving 2 mg every 2 months, which was non-inferior and clinically equivalent to the group receiving ranibizumab 0.5 mg monthly, where 94% of patients maintained vision [40]. VIEW 2 results were almost identical. In the aflibercept groups, vision was maintained in 96% of patients receiving aflibercept 0.5 mg monthly, 96% of patients receiving 2 mg monthly, and 96% of patients receiving 2 mg every 2 months. In the group receiving ranibizumab 0.5 mg monthly, 94% of patients maintained vision (Table 2) [40]. Based on these phase 3 results, aflibercept received FDA approval for the treatment of wet AMD in November 2011. The approved dose was 2 mg and the approved treatment regimen was a loading dose of 3 monthly injections followed by dosing every 8 weeks thereafter. The 2-year results were recently announced by Regeneron Pharmaceuticals, Inc. and showed sustained improvement in visual acuity. During the second year, patients received treatment on an as-required basis, when met specific treatment criteria, but at least one injection every 12 weeks [40]. In an integrated analysis of the VIEW 1 and VIEW 2 studies, the visual acuity gain from baseline in the aflibercept 2 mg every 8 weeks group at week 96 was +7.6 letters (versus +8.4 letters at week 52), with an average of 11.2 injections over 2 years and 4.2 injections during the second year. The visual acuity gain from baseline in the monthly ranibizumab group at week 96 was +7.9 letters (versus +8.7 letters at week 52, with an average of 16.5 injections over 2 years and 4.7 injections during the second year) [40]. Regarding the anatomical results, all aflibercept groups achieved reductions in central retinal thickness similar to those for monthly ranibizumab as assessed by OCT. Initially, there was a large and rapid reduction in retinal thickness evident by week 4 that was maintained to week 52. Minor fluctuations in central retinal thickness were seen in the 2 mg every 2 months group after sham injections in the VIEW 2 study. However, these fluctuations attenuated over time [40]. Aflibercept was well tolerated with very rare systemic adverse events, including arterial thromboembolic events (ATEs). The incidence of ATEs was 1.8% during the first year of the clinical trials and included non-fatal strokes, non-fatal myocardial infarction, or death from vascular events or an unknown cause. When compared to ranibizumab, differences were noted in the pre-specified analyses of intraocular pressure, with fewer aflibercept-treated patients experiencing an increase in intraocular pressure over the 52 weeks in the VIEW 1 and VIEW 2 studies.

Table 2.

Phase 3 clinical trials of aflibercept in AMD [40]

		VIEW 1			VIEW 2
		Aflibercept 2 mg q8 weeks	Aflibercept 2 mg q4 weeks	Ranibizumab 0.5 mg q4 weeks	Aflibercept 2 mg q8 weeks	Aflibercept 2 mg q4 weeks	Ranibizumab 0.5 mg q4 weeks
Number of patients		n = 301	n = 304	n = 304	n = 306	n = 309	n = 291
Maintenance of VA %		94%	95%	94%	95%	95%	95%
Mean VA improvement in letters by ETDRS		7.9	10.9	8.1	8.9	7.6	9.4
3-line improvement on the ETDRS chart %		31%	38%	31%	31%	29%	34%

AMD age-related macular degeneration, ETDRS Early Treatment Diabetic Retinopathy Study, VA visual acuity, VIEW Vascular endothelial Growth Factor (VEGF) Trap-Eye: Investigation of efficacy and safety in wet age-related macular degeneration

Discussion

Anti-VEGF therapy has improved the quality of life of patients with neovascular AMD. Ranibizumab was the first medication to not only preserve but also improve vision in patients with wet AMD. The MARINA [23] and ANCHOR [24, 41] trials established ranibizumab as an effective therapy when dosed monthly. It has been shown to stabilize vision in 94% of patients and to actually improve vision by 3 or more lines in almost 40% of patients. The PIER [42] trials showed that ranibizumab is less effective when dosed quarterly or as needed. The PRONTO study, a single investigator-sponsored trial, showed that it is possible to extend the time between as-needed injections when patients are followed closely with frequent examinations and OCT testing [43, 44]. On the other hand, there is a subcategory of patients who show little if any response to therapy with persistent or rebound increase in macular fluid. Usually patients who receive three consecutive injections of ranibizumab without anatomical resolution of intraretinal or subretinal fluid are defined as non-responders. For these patients, biweekly dosing of the medication is recommended [45].

VEGF Trap-Eye differs from established anti-VEGF therapies, having a higher binding affinity for VEGF-A and VEGF-B as well as PIGF. Phase 1 data demonstrated acceptable safety and tolerability of VEGF Trap-Eye in the treatment of neovascular AMD. In phase 2 studies, patients dosed in a similar fashion to ranibizumab demonstrated stabilization of their vision at 1 year. Two phase 3 studies showed at year 1 that aflibercept can be dosed every 2 months after three initial monthly injections with equivalent results to monthly ranibizumab. During the second year, the number of as-required injections is less compared to ranibizumab. Furthermore, a recent retrospective study showed that patients who do not respond to ranibizumab have better visual and anatomical outcomes when switched to aflibercept [46].

Currently, the main issue with anti-VEGF therapy is the cost and the number of office visits per patient [47]. At a cost of approximately $2,000 per injection, the cost to treat wet AMD patients in the US exceeds $10 billion per year. The CATT study showed that bevacizumab, which costs $15–50 per injection, has similar efficacy to ranibizumab when dosed monthly. Due to the high cost, many ophthalmologists have turned to bevacizumab as the alternative intravitreal agent in the treatment of wet AMD. On the other hand, aflibercept is more expensive than bevacizumab, but as effective as ranibizumab when dosed bimonthly and offers the advantage of less frequent injections. Every intraocular injection poses a risk of infection (1 in 4,000 to 1 in 8,000) and is uncomfortable for the patient. The decision of which medication to choose should be based on the clinician’s judgment and the patient’s response to treatment. Conducting another clinical trial comparing all three medications would be an option, but we would most likely fail to show a clear difference since all medications appear effective using their labeled dosing regimen. Therefore, the clinician needs to decide which medication to use based on each individual circumstance. However, the cost of treatment, insurance coverage, and frequency of injections seem to alter therapy on an individual basis.

Future Perspective

Aflibercept is one of three effective medications for the treatment of neovascular AMD. The true impact of this drug is that it has a longer t½ and higher binding affinity for VEGF-A; therefore, it can reduce the number of intraocular injections and office visits. This was the rational and the benefit behind the development of this new medication. However, neither of the available medications causes complete regression of the choroidal neovascular membrane, which is the hallmark of the disease. Based on the natural history of the disease, the abnormal capillaries that constitute the membrane continue leaking fluid until a scar is formed in the macula and the patient becomes legally blind. The focus over the next decade will be to identify new targets that can prevent or reverse choroidal revascularization. Also, it is of utmost importance to develop even longer-acting therapies. Slow-release implant formulations of current medications (e.g., ranibizumab reservoirs) are under investigation, but hold many technical difficulties given the nature and the molecular weight of the medications. Different drug formulations that could be used and eye drops are another solution to the problem of monthly injections, but so far all the drugs that have been tested have failed. Currently, there are many drugs under investigation (e.g., platelet-derived growth factor inhibitors) and the primary effect is inhibition of angiogenesis. With so many new effective agents against angiogenesis, we have an obligation to continue translational and clinical research to identify new treatments for AMD.